ANALYSIS OF THE CURRENT STATE AND THE DYNAMICS OF LIPID-LOWERING DRUGS IN THE PHARMACEUTICAL MARKET OF UKRAINE
DOI:
https://doi.org/10.22159/ajpcr.2018.v11i6.22702Keywords:
Lipid-lowering drugs, Pharmaceutical market in Ukraine, AccessibilityAbstract
Objective: The purpose of this study was to analyze the assortment, availability, consumption status, and dynamics of lipid-lowering drugs in the pharmaceutical market in Ukraine.
Methods: Among the primary methods of research were applied the following: System and content analysis, marketing, logical and mathematical analysis, graphical mode, and also a way of detailed and abstract simulation and synthesis.
Results: The ratio of imported and domestic lipid-lowering drugs in Ukrainian pharmaceutical market was analyzed (imported lipid-lowering medicines account for 82% of the total number of this group in Ukrainian market, the share of local medications is 18%, respectively). The structural review and analysis of market characteristics of 5-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors group of medicines (sales, accessibility for people, and competitiveness) were conducted, and the most promising market segment for producers and distributors was identified. The most promising sector is rosuvastatin, which is characterized by an average sales volume with a tendency to increase and a high increasing profit.
Conclusion: Data on dynamics of the development of lipid-lowering drugs segment in the pharmaceutical market of Ukraine are systematized, which enables potential manufacturers to identify their market niche. As a result of the study, heavy dependency on imported lipid-lowering drugs in the pharmaceutical market of Ukraine was established, which determines low economic accessibility (especially in case of increasing in exchange rates) and physical availability (dependence on the regularity of shipments to Ukraine) for consumers. The most competitive medicines of atorvastatin and rosuvastatin group were determined, it was established that sales leader was pharmaceutical company KRKA dd, Novo Mesto (Slovenia) with generics Atoris and Roxer.
Downloads
References
WHO. Cardiovascular Diseases (CVDs). Media Center, Fact Sheet. Geneva: World Health Organization. Available from: http://www.who. int/mediacentre/factsheets/fs317/en. [Last updated on 2017 2015 Jan 13; Last cited on 2017 Jul 21].
Andhuvan G, Ayyappan P, Sahana C, Poovizhi S, Sivasakthi K. Knowledge of modifiable risk factors of heart disease among patients with cardiovascular risk. Asian J Pharm Clin Res 2017;10:99-102.
Mendis S, Puska P, Norrving B, editors. Global Atlas on Cardiovascular Disease Prevention and Control. Geneva: World Health Organization; 2011.
Center for Health Statistics Ministry of Health of Ukraine. Center for Health Statistics Ministry of Health of Ukraine. Database of Medical-Statistical Information Health for All†Kyiv: Center for Health Statistics Ministry of Health of Ukraine; 2009. Available from: http:// www.medstat.gov.ua/ukr/news.html?id=203/. Ukraine. [Last updated on 2017 Aug 23; Last cited on 2017 Sep 20].
Affandi MM, Tripathy M, Majeed A. The prospect, promises and hindrances of statin base molecules: Look back to look forward. Int J Pharm Pharm Sci 2016;8:22-33.
Cahyawati PN, Sari DC, Romi MM, Arfian N. Simvastatin attenuates renal failure in mice with A 5/6 subtotal nephrectomy. Int J Pharm Pharm Sci 2017;9:12-7.
Jacobson TA, Maki KC, Orringer CE, Jones PH, Kris-Etherton P, Sikand G, et al. National lipid association recommendations for patient-centered management of dyslipidemia: Part 2. J Clin Lipidol 2015;9:S1-122.e1.
Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, et al. Heart disease and stroke statistics--2015 update: A report from the American heart association. Circulation 2015;131:e29-322.
Mnushko ZM, Pestun IV, Timanyuk IV, Sofronova IV, Aliekperova NV. Management and Marketing in Pharmacy: The Textbook for International Students of Higher Pharmaceutical Schools in 2 Parts. Part II: Marketing in Pharmacy. Kharkiv: Dialog; 2016.
Derzhavnyy Reyestr Likars’kikh Zasobiv Ukrayiny. [Medicines State Register of Ukraine]. Kyiv: Ministry of Health of Ukraine; c2004-2017; Available from: http://www.drlz.kiev.ua/. Ukrainian. [Last updated on 2017 Jul 22; Last cited on 2017 Jul 22].
Morion 1999-2017: Spetsializovane Medychne Internet-Vydannya Dlya Likariv, Provizoriv, Farmatsevtiv, Studentiv Medychnykh ta Farmatsevtychnykh Vyshiv [Specialized Medical Online Edition for Doctors, Pharmacists, Students of Medical and Pharmaceutical Universities]. Kyiv; c1999-2017; ATC Classification. Available from: http://www.compendium.com.ua/. Ukrainian, Russian. [Last cited on 2017 Jul 22].
CR Consumer Reports. Consumer Reports; c2006-2017. Are You Taking the Right Treatment for Your High Cholesterol? 2014. Available from: https://www.consumerreports.org/cro/2014/03/treating-high-cholesterol-with-statins/index.htm. [Last cited on 2017 Jul 22].
Medpharmconnect. Kyiv: Medpharmconnect: The Medical Portal for Physicians; c2010. Company COMCON Pharma-Ukraine Conducted Monitoring of Statin Prescriptions; 2015. Available from: http://www. medpharmconnect.com/Isledovania/survey_results/20598.htm. [Last cited on 2017 Feb 16].
Hasan MM, Islam MF, Rahaman MM, Habib AM, Maniruzzaman M. An overview of the current status of prescribing pattern of statin molecules to prevent dyslipidemia in Bangladesh. Int J Innov Pharm Sci Res 2015;3:386-94.
Statista: The Statistics Portal. Top HMG-CoA Reductase Inhibitors by U.S. Prescription Market Share in 2013. Available from: https:// www.statista.com/statistics/311999/cholesterol-lowering-drugs-by-us-prescription-market-share. [Last cited on 2017 Jul 22].
Published
How to Cite
Issue
Section
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.
